Trial Profile
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Extended Registry
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Coronary artery disease; Stent thrombosis
- Focus Therapeutic Use
- Acronyms IDEAL-PCI ext
- 25 Jan 2018 Status changed from recruiting to withdrawn prior to enrolment due to regulatory reasons.
- 30 Nov 2016 New trial record